Literature DB >> 7097961

On the nature and ethics of phase I clinical trials of cancer chemotherapies.

M B Lipsett.   

Abstract

Entities:  

Keywords:  Biomedical and Behavioral Research

Mesh：

Substances：

Year:  1982        PMID： 7097961

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  11 in total

1.  Strategies to minimize risks and exploitation in phase one trials on healthy subjects.

Authors:  Adil E Shamoo; David B Resnik
Journal:  Am J Bioeth       Date:  2006 May-Jun       Impact factor: 11.229

2.  Therapeutic optimism in the consent forms of phase 1 gene transfer trials: an empirical analysis.

Authors:  J Kimmelman; N Palmour
Journal:  J Med Ethics       Date:  2005-04       Impact factor: 2.903

3.  Justification of the starting dose as the main determinant of accrual time in dose-seeking oncology phase 1 trials.

Authors:  Nicolas Penel; Pierre Leblond; Amélie Lansiaux; Stéphanie Clisant; Eric Dansin; Antoine Adenis; Jacques Bonneterre
Journal:  Invest New Drugs       Date:  2009-09-16       Impact factor: 3.850

4.  Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse.

Authors:  Rajul K Jain; J Jack Lee; David Hong; Maurie Markman; Jing Gong; Aung Naing; Jennifer Wheler; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

5.  Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study.

Authors:  N R Cutler; J J Sramek
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

6.  Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies.

Authors:  Rajul K Jain; J Jack Lee; Chaan Ng; David Hong; Jing Gong; Aung Naing; Jennifer Wheler; Razelle Kurzrock
Journal:  J Clin Oncol       Date:  2012-06-11       Impact factor: 44.544

7.  Survival and clinical outcomes of patients with ovarian cancer who were treated on phase 1 clinical trials.

Authors:  Bradley R Corr; Marisa Moroney; Jeanelle Sheeder; S Gail Eckhardt; Brandon Sawyer; Kian Behbakht; Jennifer R Diamond
Journal:  Cancer       Date:  2020-07-22       Impact factor: 6.860

8.  Patients in phase I trials of anti-cancer agents in Japan: motivation, comprehension and expectations.

Authors:  K Itoh; Y Sasaki; H Fujii; T Ohtsu; H Wakita; T Igarashi; K Abe
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 9.  Altruism: Scoping review of the literature and future directions for HIV cure-related research.

Authors:  Karine Dubé; Kelly E Perry; Kushagra Mathur; Megan Lo; Sogol S Javadi; Hursch Patel; Susanna Concha-Garcia; Jeff Taylor; Andy Kaytes; Lynda Dee; Danielle Campbell; John Kanazawa; David Smith; Sara Gianella; Judith D Auerbach; Parya Saberi; John A Sauceda
Journal:  J Virus Erad       Date:  2020-08-25

10.  Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology.

Authors:  Joeri A J Douma; Laurien M Buffart; Ramy Sedhom; Mariette Labots; Willemien C Menke-van der Houven van Oordt; Mikkjal Skardhamar; Anthony De Felice; Esther Lee; Divya Dharmaraj; Nilofer S Azad; Michael A Carducci; Henk M W Verheul
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.